WO1990003175A1 - Selenium compositions for treatment of disease - Google Patents
Selenium compositions for treatment of disease Download PDFInfo
- Publication number
- WO1990003175A1 WO1990003175A1 PCT/US1989/004218 US8904218W WO9003175A1 WO 1990003175 A1 WO1990003175 A1 WO 1990003175A1 US 8904218 W US8904218 W US 8904218W WO 9003175 A1 WO9003175 A1 WO 9003175A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- selenium
- oil
- reaction product
- red
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
Definitions
- the present invention concerns certain selenium compositions, methods for preparing such compositions, and methods for treating different conditions and diseases.
- the present invention relates to a method for preparing a bivalent negative selenium composition which comprises mixing gray selenium powder with an animal oil, vegetable oil, fish oil, or mixture thereof to form a suspension; heating the suspension to a sufficient temperature to form a red selenium/oil reaction product; and cooling the reaction product to recover a bivalent negative selenium composition containing between 0.1 and 2 weight percent red selenium.
- the suspension is heated to about 150 to 200°C for a sufficent time to form a red selenium composition having at least about l weight percent selenium in the oil, and the oil is tung oil.
- the invention also relates to a method for preparing a bivalent negative selenium composition which comprises exothermically reacting selenium monochloride or selenium monobromide with an animal, vegetable or fish oil to form a red-selenium/oil reaction product containing between 0.1 and 2 weight percent selenium.
- preferred oils include sesame, safflower, tung, corn, sardine, cod liver, or salmon oil.
- This method further comprises adding an oxidant to the oil prior to adding the selenium compound, wherein the oxidant is a 3-ketone, preferably 3-pentanove or 3-heptanone.
- the invention also relates to the red-selenium oil reaction products produced by these methods, along with methods for treating the effects of an anabolic condition in
- this method treats the effects of an anabolic condition in a patient by administering to the patient a sufficient amount of a red-selenium/oil reaction product containing 0.1 to 5 weight percent selenium.
- the amount of reaction product to be administered ranges from about one to 100 drops per dose, each dose administered between 2 and six times per day.
- the bivalent negative selenium in its different preparations, has a salutary effect, especially upon pathological conditions when they have an anabolic character.
- pathological conditions are the neoplastic conditions, arthritis, arteriosclerosis, epilepsy, convulsions, arrythmia, mania, sclerosis, cyrrhosis, inconsolidated fractions, dermatoses, drug, alcohol, smoking, addiction, different viral infections, as AIDS, the common cold and others, and acid symptoms such as acid pain, itching, vertigo, dyspnea and impaired hearing.
- such a colloidal red selenium compound is obtained through an exothermic reaction resulting from mixing selenium monobromide or monochloride with an oil - or a preparation which has an oil or a material with a lipidic character in its constitution.
- STITUTE SH «T co pound is used in suspensions having preferably the selenium from 0.1% to 5%. This proportion is not limitative.
- red selenium is obtained by progressively heating a mixture of gray selenium powder and an oil, preferably tung oil, until the suspended selenium is changed i.nto a red seleni.um. Agi.tati.ng the mixture by strong stirring facilitates this reaction. The reaction product is evidenced by a reddish color. The mixture is then cooled and the red selenium is incorporated in the fatty acid molecules.
- the red selenium composition described above can be obtained with any compound having lipidic properties.
- lipidic products include any animal, vegetable or fish oil, and more particularly, oils of sesame, safflower, tung, corn, cod liver, sardine, salmon or other fish, suspensions or solutions of phospholipids or animal bodies or organs, such as thymus, intestines, spleen, liver or others, lecithins of eggs, soya beans, Bixa seeds, phospholipids of other plants fungi, especially of those used to produce antibiotics, microbes, milk, colostrum, aminoacids, alkaline and acid aminoacid, proteose, peptones, histones, nucleoproteins and others.
- the selenium monobromide or monochloride is mixed with a lipidic preparation, preferably having an oil or a fatty acid compound in its constitution.
- selenium monobromide or nonochloride Especially good preparations are obtained by mixing the selenium monobromide or nonochloride with tung oil, saf lower or fish oils or their fatty acids.
- the selenium monobromide or nonochloride is added in a proportion so as to result in a selenium/oil reaction product containing between 0.1 % to 5% percent red selenium.
- the products of the invention are administered orally or by injections in repeated doses preferably between 2 and six, most preferably four times per day, each dose containing between from one drop and 100 drops (5 ml) according to the concentration of the selenium in the oil and of the specific condition to be treated. No toxic effects or side effects are seen, the products of the invention being particularly well tolerated by patients.
- the products of the invention are administered orally or by injections, preferably intramuscularly or into the lesion itself.
- Very characteristic favorable subjective effects as on pain are in general obtained in very short time, indicating a more rapid action which was not seen with other selenium compounds.
- the same, the objective changes are obtained also in special short time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Bivalent negative selenium compositions of a red selenium/oil reaction product, methods of preparing such products, and methods for administering such products to patients to treat anabolic conditions.
Description
SELENIUM COMPOSITIONS FOR TREATMENT OF DISEASE
Technical Field
The present invention concerns certain selenium compositions, methods for preparing such compositions, and methods for treating different conditions and diseases.
Summary of the Invention
The present invention relates to a method for preparing a bivalent negative selenium composition which comprises mixing gray selenium powder with an animal oil, vegetable oil, fish oil, or mixture thereof to form a suspension; heating the suspension to a sufficient temperature to form a red selenium/oil reaction product; and cooling the reaction product to recover a bivalent negative selenium composition containing between 0.1 and 2 weight percent red selenium. Preferably, the suspension is heated to about 150 to 200°C for a sufficent time to form a red selenium composition having at least about l weight percent selenium in the oil, and the oil is tung oil.
The invention also relates to a method for preparing a bivalent negative selenium composition which comprises exothermically reacting selenium monochloride or selenium monobromide with an animal, vegetable or fish oil to form a red-selenium/oil reaction product containing between 0.1 and 2 weight percent selenium.. In this embodiment, preferred oils include sesame, safflower, tung, corn, sardine, cod liver, or salmon oil. This method further comprises adding an oxidant to the oil prior to adding the selenium compound, wherein the oxidant is a 3-ketone, preferably 3-pentanove or 3-heptanone.
The invention also relates to the red-selenium oil reaction products produced by these methods, along with methods for treating the effects of an anabolic condition in
SUBSTITUTE SHEET
__. -
a patient which comprises administering to the patient a sufficient amount of one of these reaction products. Specifically, this method treats the effects of an anabolic condition in a patient by administering to the patient a sufficient amount of a red-selenium/oil reaction product containing 0.1 to 5 weight percent selenium. In these methods, the amount of reaction product to be administered ranges from about one to 100 drops per dose, each dose administered between 2 and six times per day.
Description of the Invention
I have found that the bivalent negative selenium, in its different preparations, has a salutary effect, especially upon pathological conditions when they have an anabolic character. Such conditions are the neoplastic conditions, arthritis, arteriosclerosis, epilepsy, convulsions, arrythmia, mania, sclerosis, cyrrhosis, inconsolidated fractions, dermatoses, drug, alcohol, smoking, addiction, different viral infections, as AIDS, the common cold and others, and acid symptoms such as acid pain, itching, vertigo, dyspnea and impaired hearing.
I have found that good results are particularly obtained with the administration of a bivalent negative red selenium composition.
I have further found that especially active and with a minimal toxicity are the preparations in which the red selenium is a colloidal compound.
According to one embodiment of the. invention such a colloidal red selenium compound is obtained through an exothermic reaction resulting from mixing selenium monobromide or monochloride with an oil - or a preparation which has an oil or a material with a lipidic character in its constitution.
The product of the invention, colloidal red selenium
STITUTE SH«T
co pound, is used in suspensions having preferably the selenium from 0.1% to 5%. This proportion is not limitative.
In another form of the invention, red selenium is obtained by progressively heating a mixture of gray selenium powder and an oil, preferably tung oil, until the suspended selenium is changed i.nto a red seleni.um. Agi.tati.ng the mixture by strong stirring facilitates this reaction. The reaction product is evidenced by a reddish color. The mixture is then cooled and the red selenium is incorporated in the fatty acid molecules.
By further heating of the mixture, an exothermic reaction rakes place resulting in an undesirable and non- useful brown color reaction product.
I have found that the product of the first reddish color has a much stronger pharmacological action than the last brown incorporated product. These changes are still more manifest for the reddish color selenium incorporation in the tung oil, wherein the amount of incorporated selenium ranges from 0.1 to about 5% by weight.
The red selenium composition described above can be obtained with any compound having lipidic properties. Such lipidic products include any animal, vegetable or fish oil, and more particularly, oils of sesame, safflower, tung, corn, cod liver, sardine, salmon or other fish, suspensions or solutions of phospholipids or animal bodies or organs, such as thymus, intestines, spleen, liver or others, lecithins of eggs, soya beans, Bixa seeds, phospholipids of other plants fungi, especially of those used to produce antibiotics, microbes, milk, colostrum, aminoacids, alkaline and acid aminoacid, proteose, peptones, histones, nucleoproteins and others.
This enumeration is not limitative as to the material to which the red colloidal selenium is mixed, apporting its properties and consequently its use as applied to biological entities.
?' ?HSTiTUTΞ SHEET
I have shown that these reaction products have a manifest antineoplastic action - when administered orally, even in small amounts.
As noted above, by mixing selenium monobromide or monochloride with an oil, an exothermic reaction takes place resulting in a red selenium colloidal compound. I have further found that by adding to the red colloidal compound an oxidant its action is enhanced. A good preparation is obtained by having the colloidal red selenium administered together with 3-ketones agents such as 3-pentanone and 3- heptanone or with other oxidizing agents. I have found that as oily material the use of a preparation having equal amounts of 3-pentanone and/or 3-heptanone in an oil, results in a specially active antineoplastic preparation for the mixture with the selenium monobromide or monochloride.
According to the invention, the selenium monobromide or monochloride is mixed with a lipidic preparation, preferably having an oil or a fatty acid compound in its constitution.
Especially good preparations are obtained by mixing the selenium monobromide or nonochloride with tung oil, saf lower or fish oils or their fatty acids. In the different mixtures, the selenium monobromide or nonochloride is added in a proportion so as to result in a selenium/oil reaction product containing between 0.1 % to 5% percent red selenium.
The products of the invention are administered orally or by injections in repeated doses preferably between 2 and six, most preferably four times per day, each dose containing between from one drop and 100 drops (5 ml) according to the concentration of the selenium in the oil and of the specific condition to be treated. No toxic effects or side effects are seen, the products of the invention being particularly well tolerated by patients.
The preparation of the invention due to the action of bivalent negative selenium as part of a lipid and of the
SUBSTITUTE SHEET
fatty acids proper to the tung oil has a manifest antiana- bolic action. Thus, it is useful for treating the effects of anabolic conditions, such as alcohol, smoking or drug addiction. It has also shown special favorable effects, both subjective and objective, upon various neoplastic conditions.
The products of the invention are administered orally or by injections, preferably intramuscularly or into the lesion itself. Very characteristic, favorable subjective effects as on pain are in general obtained in very short time, indicating a more rapid action which was not seen with other selenium compounds. The same, the objective changes are obtained also in special short time.
The experimental and clinical research have thus shown the exceptional therapeutic value of the red selenium and especially of its colloidal form - with a very low toxicity, especially in the minimal amounts necessary. It appears rapidly absorbed and consequently active even in the exceptional small amounts used.
As the subjective and objective effects upon the neoplastic diseases are generally seen, even with very little amounts, and within a short time, the method represents an important progress in the treatment of these conditions.
While it is apparent that the invention herein disclosed is well calculated to fulfill the desired results, it will be appreciated that numerous modifications and embodiments may be devised by those skilled in the art, and it is intended that the appended claims cover all such modifications and embodiments as fall within the true spirit and scope of the present invention.
EET
Claims
1. A method for preparing a bivalent negative seleniu composition which comprises: mixing gray selenium powder with an animal oil, vegetable oil, fish oil, or mixture thereof to form a suspension; heating the suspension to a sufficient temperatur to form a red selenium/oil reaction product; and cooling the reaction product to recover a bivalen negative selenium composition containing between 0.1 and 2 weight percent red selenium.
2. The method of claim 1 wherein the suspensionis heated to about 150 to 200βC for a sufficent time to form a red selenium composition having at least about 1 weight percent selenium in the oil.
3. The method of claim 1 wherein the oil is tung oil.
4. A method for preparing a bivalent negative seleniu composition which comprises: exothermically reacting selenium monochloride or selenium monobromide with an animal, vegetable or fish oil form a red-selenium/oil reaction product containing between 0.1 and 2 weight percent selenium.
5. The method of claim 4 wherein the oil is sesame, safflower, tung, corn, sardine, cod liver, or salmon oil.
6. The method of claim 4 further comprising adding an oxidant to the oil prior to adding the selenium compound.
7. The method of claim 6 wherein the oxidant is a 3- ketone.
8. The method of claim 7 wherein the 3-ketone is 3- pentanone or 3-heptanone.
9. The red-selenium oil reaction product of claim 1.
SUBSTITUTE SHEET
10. The red-selenium oil reaction product of claim 4.
11. The red-selenium oil reaction product of claim 8.
12. A method of treating the effects of an anabolic condition in a patient which comprises administering to sai patient a sufficient amount of the reaction product of claim 9.
13. A method of treating the effects of an anabolic condition in a patient which comprises administering to said
- patient a sufficient amount of the reaction product of claim* 10.
14. A method of treating the effects of an anabolic condition in a patient which comprises administering to said patient a sufficient amount of the reaction product of claim 11.
15. The method of claim 12 wherein the amount of reaction product to be administered ranges from about one to 100 drops per dose, each dose administered between 2 and six times per day.
16. The method of claim 13 wherein the amount of reaction product to be administered ranges from about one to 100 drops per dose, each dose administered between 2 and six times per day.
17. The method of claim 14 wherein the amount of reaction product to be administered ranges from about one to 100 drops per dose, each dose administered between 2 and six times per day.
18. A method of treating the effects of an anabolic condition in a patient which comprises administering to said patient two drops of a red-selenium/oil reaction product containing 0.1 to 5 weight percent selenium four times fper day.
19. The method of claim 18 wherein the red-selenium/σil reaction product contains 1 weight percent selenium and one drop four times per day is administered.
20.. The method of claim 19 wherein the oil is tung oil.
SUBSTITUTE SHEET
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24991588A | 1988-09-27 | 1988-09-27 | |
US249,915 | 1988-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990003175A1 true WO1990003175A1 (en) | 1990-04-05 |
Family
ID=22945558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1989/004218 WO1990003175A1 (en) | 1988-09-27 | 1989-09-27 | Selenium compositions for treatment of disease |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1990003175A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2541121C1 (en) * | 2014-04-07 | 2015-02-10 | Общество с ограниченной ответственностью "НаноФарм-про" | Agent for intracellular delivery of biologically high-molecular compound of nanoparticles and method for preparing it |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4564634A (en) * | 1982-05-28 | 1986-01-14 | F.C.N.S.R.L. | Selenium compounds having antineoplastic activity, process for the preparation thereof and pharmaceutical compositions therefrom |
US4681753A (en) * | 1983-03-08 | 1987-07-21 | F.C.N.S.R.L. | Pharmaceutical compositions having antineoplastic activity |
US4851437A (en) * | 1986-08-12 | 1989-07-25 | Elena Avram | Tung oil compositions and use for treatment of body deficiencies |
-
1989
- 1989-09-27 WO PCT/US1989/004218 patent/WO1990003175A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4564634A (en) * | 1982-05-28 | 1986-01-14 | F.C.N.S.R.L. | Selenium compounds having antineoplastic activity, process for the preparation thereof and pharmaceutical compositions therefrom |
US4681753A (en) * | 1983-03-08 | 1987-07-21 | F.C.N.S.R.L. | Pharmaceutical compositions having antineoplastic activity |
US4851437A (en) * | 1986-08-12 | 1989-07-25 | Elena Avram | Tung oil compositions and use for treatment of body deficiencies |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2541121C1 (en) * | 2014-04-07 | 2015-02-10 | Общество с ограниченной ответственностью "НаноФарм-про" | Agent for intracellular delivery of biologically high-molecular compound of nanoparticles and method for preparing it |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5650157A (en) | Pharmaceutical compositions and methods | |
DE3789576T2 (en) | Use of inositol triphosphate to treat metal poisoning. | |
DE69730688T2 (en) | ORAL DRUG APPLICATION | |
EP0754457B1 (en) | Antiobestic agent | |
DE60200256T3 (en) | Basic protein fraction from milk as an active ingredient for the reduction of high blood pressure | |
JP2002540807A (en) | Dietary supplement derived from fermented milk for the prevention of osteoporosis | |
DE68909053T2 (en) | TRIGLYCERIDES, FOOD COMPOSITION THEREOF AND THEIR USE AS FOODSTUFFS. | |
DE69331465T2 (en) | INTRAVENOUS SOLUTION THAT REDUCES PROTEIN AND WATER LOSS IN THE BODY | |
CA1222699A (en) | Pharmaceutical preparation for digestive ulcer | |
DE2921852A1 (en) | LIPID LOWERING AGENT | |
JP3622985B2 (en) | How to increase magnesium absorption and prevent atherosclerosis | |
WO1990003175A1 (en) | Selenium compositions for treatment of disease | |
DE69430416T2 (en) | Amino acid compositions for the treatment of infections | |
DE60216523T2 (en) | PREPARATION AND USE OF SOY PROTEIN HYDROLYSATES ENRICHED WITH BRANCHED AMINO ACIDS | |
DE3853493T2 (en) | Superoxide dismutase derivatives, process for their preparation and their use as medicines. | |
PT79649B (en) | Process for preparing pharmaceutical compositions for therapeutical treatment of rheumatic diseases containing oxicam derivatives and 1,2-diacylglycero-3-phosphocholine | |
DE69531554T2 (en) | USE OF INOSITE TRIPHOSPHATE FOR THE PRODUCTION OF MEDICINAL PRODUCTS | |
DE69522723T2 (en) | Anti-allergic agent and nutritional composition containing glutamine | |
US4851398A (en) | Bismuth containing pharmaceutical compositions | |
US6686392B1 (en) | Lipidic zinc compounds and use for treatment of prostatic hypertrophy | |
EP0506651A2 (en) | Pharmaceutical preparation based on plasma proteins | |
US4677118A (en) | Composition and method for treatment of copper deficiency | |
US4649152A (en) | Composition and method for treatment of potassium deficiency | |
DE2638088B2 (en) | Use of sweet whey powder | |
CA1303498C (en) | Composition and method for treatment of copper deficiency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): BR JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |